Product Code: GMDHC11476IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 4, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development
- Alivio Therapeutics Inc
- GlycoMira Therapeutics Inc
- Grunenthal GmbH
- Harrow Health Inc
- Kyorin Pharmaceutical Co Ltd
- Lipella Pharmaceuticals Inc
- Mirae Cell Bio Co Ltd
- Pierre Fabre Pharmaceuticals Inc
- UCB SA
- Urigen Pharmaceuticals Inc
- Xigen SA
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles
- (heparin sodium + lidocaine hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- brimapitide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- certolizumab pegol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dimethyl sulfoxide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- F-16357 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GM-0111 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GRT-6010 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lidocaine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LP-08 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MAY-88 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NEO-5937 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- onabotulinumtoxinA - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pentosan polysulfate sodium - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- URG-801 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products
- Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones
- Featured News & Press Releases
- Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women's Health Conference
- Sep 12, 2018: U.S. Department of Defense awards $3.3 million grant to Alivio Therapeutics
- Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
- May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
- Jun 30, 2011: Urigen Provides Development Update For URG101
- Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
- Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
- Apr 23, 2010: Urigen Files Request For FDA Meeting
- Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
- Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
- Apr 25, 2008: Urigen Announces US Patent Office Notice Of Allowance Of Claims For URG101
- Apr 07, 2008: Urigen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Analysis Results
- Dec 05, 2007: Urigen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
